What is Neurocrine Biosciences, Inc. Quarterly Revenue?

Neurocrine Biosciences, Inc. Quarterly Revenue Neurocrine Biosciences Inc Jun-2026 Quarterly Revenue is $959 Million which is growth of 39.5% YoY.

What is Neurocrine Biosciences, Inc. Quarterly Net Profit?

Neurocrine Biosciences, Inc. Quarterly Net Profit Neurocrine Biosciences Inc Jun-2026 Quarterly Net Profit is $144 Million which is growth of 34.3% YoY.

What is Neurocrine Biosciences, Inc. Annual Revenue?

Neurocrine Biosciences, Inc. Annual Revenue Neurocrine Biosciences Inc Dec-2025 Annual Revenue is $2,860 Million which is growth of 21.4% YoY.

What is Neurocrine Biosciences, Inc. Annual Net Profit?

Neurocrine Biosciences, Inc. Annual Net Profit Neurocrine Biosciences Inc Dec-2025 Annual Net Profit is $479 Million which is growth of 40.2% YoY.

What is Neurocrine Biosciences, Inc. Total Shareholders Fund?

Neurocrine Biosciences, Inc. Total Shareholders Fund Neurocrine Biosciences Inc Dec-2025 Total Shareholders Fund is $3,253 Million which is growth of 25.6% YoY.

What is Neurocrine Biosciences, Inc. Total Assets?

Neurocrine Biosciences, Inc. Total Assets Neurocrine Biosciences Inc Dec-2025 Total Assets is $4,632 Million which is growth of 24.5% YoY.

What is Neurocrine Biosciences, Inc. Book Value Per Share?

Neurocrine Biosciences, Inc. Book Value Per Share Neurocrine Biosciences Inc Book Value Per Share is $32 which is growth of 24.2% YoY.

What is Neurocrine Biosciences, Inc. ROE?

Neurocrine Biosciences, Inc. ROE Neurocrine Biosciences Inc ROE is 0% which is growth of 0% YoY.

What is Neurocrine Biosciences, Inc. Cash From Operating Activity?

Neurocrine Biosciences, Inc. Cash From Operating Activity Neurocrine Biosciences Inc Dec-2025 Cash From Operating Activity is $783 Million which is growth of 31.5% YoY.

What is Neurocrine Biosciences, Inc. Net Cash Flow?

Neurocrine Biosciences, Inc. Net Cash Flow Neurocrine Biosciences Inc Dec-2025 Net Cash Flow is $480 Million which is growth of 2751.9% YoY.

Neurocrine Biosciences, Inc.

XNAS: NBIX

Await Turnaround

Download real time

-6.24(-4.41%)

27.40% Fall from 52W High

1.6M

XNAS Volume

XNAS 13 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Neurocrine Biosciences Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Neurocrine Biosciences Inc share price target, revenues, EPS, net income and more

Neurocrine Biosciences Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Neurocrine Biosciences Inc Jun-2026 Quarterly Revenue is $959 Million which is growth of 39.5% YoY.
POSITIVE
Quarterly Net Profit Neurocrine Biosciences Inc Jun-2026 Quarterly Net Profit is $144 Million which is growth of 34.3% YoY.

Neurocrine Biosciences, Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	959	814.5	805.5	794.9	687.5	572.6	627.7	622.1	590.2	515.3	515.2	498.8	452.7
CostOfRevenue_Q Cost Of Rev.	23.2	13.8	17.6	14	11.3	9.2	9.3	8	9.2	7.5	8.5	11.2	11.5
GrossProfit_Q Gross Profit	935.8	800.7	787.9	780.9	676.2	563.4	618.4	614.1	581	507.8	506.7	487.6	441.2
OEXPNS_Q Operating Exp. ⌄	782.8	614.7	560	541.6	530.6	539.7	473.4	429.3	433.1	402.5	356.4	346.4	367.6
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	439.7	318.5	301.8	291.6	286.3	276.5	287.8	234.3	242	243.1	218.9	204.2	221.8
ResearchAndDevlopmentExpenses_Q RnD Exp.	326.7	296.2	258.2	250	244.3	263.2	185.6	195	191.1	159.4	137.5	142.2	145.8
OP_Q Operating Profit	153	186	227.9	239.3	145.6	23.7	145	184.8	147.9	105.3	150.3	141.2	73.6
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	-2.9	-	-	-	-	-	-	-	-49.7	-1.1	-1.1	-1.1	-1.5
Others_Q Other Interest Earned	-	-	-	-	-	-	-	-	-	-	-	-	-
IntExpNonOperating_Q Interest Exp. Non Operating	2.9	-	-	-	-	-	-	-	49.7	1.1	1.1	1.1	1.5
PBT_Q Profit Before Tax	162.2	246.8	239.4	291.8	159.5	14.7	162.6	190.3	98.6	34.5	198.2	115.6	121.6
TAX_Q Tax	17.8	48.9	85.7	82.3	52	6.8	59.5	60.5	33.6	-8.9	50.5	32.5	26.1
NICommonStockholders_Q Net Income Common Stockholders ⌄	144.4	197.9	153.7	209.5	107.5	7.9	103.1	129.8	65	43.4	147.7	83.1	95.5
NP_Q Net Profit	144.4	197.9	153.7	209.5	107.5	7.9	103.1	129.8	65	43.4	147.7	83.1	95.5
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	144.4	197.9	153.7	209.5	107.5	7.9	103.1	129.8	65	43.4	147.7	83.1	95.5
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	144.4	197.9	153.7	209.5	107.5	7.9	103.1	129.8	65	43.4	147.7	83.1	95.5
EPS_Q Basic EPS	1.4	2	1.5	2.1	1.1	0.1	1	1.3	0.6	0.4	1.5	0.9	1
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	2.9	1.9	1.9	2.2	1.7	0.7	1.7	1.8	1.6	1.2	1.5	1.5	1.3
SHARE_Q Number Of Shares End	101	100.5	100.1	99.4	99	99.7	99.8	101.1	100.8	99.8	98.3	97.9	97.6
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	144.4	197.9	153.7	209.5	107.5	7.9	103.1	129.8	65	43.4	147.7	83.1	95.5
NormalizedIncome_Q Normalized Income	296.7	200.5	194.6	222.1	166.2	71.5	173.4	189.2	168.9	124.8	157.7	156.1	125.7
InterestIncome_Q Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-
INT_Q Interest	2.9	-	-	-	-	-	-	-	49.7	1.1	1.1	1.1	1.5
NetInterestIncome_Q Net Interest Income	-2.9	-	-	-	-	-	-	-	-49.7	-1.1	-1.1	-1.1	-1.5
EBIT_Q EBIT	165.1	246.8	239.4	291.8	159.5	14.7	162.6	190.3	98.6	35.6	199.3	116.7	123.1
EBITDA_Q EBITDA	189.9	254.1	246.9	299.5	166.8	22.3	169.7	196.8	105.9	41.8	205	122.2	128.2
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	14.8	13.8	17.6	14	11.3	9.2	9.3	8	9.2	7.5	8.5	11.2	11.5
ReconciledDepreciation_Q Reconciled Depr.	24.8	7.3	7.5	7.7	7.3	7.6	7.1	6.5	7.3	6.2	5.7	5.5	5.1
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	144.4	197.9	153.7	209.5	107.5	7.9	103.1	129.8	65	43.4	147.7	83.1	95.5
NormalizedEBITDA_Q Normalized EBITDA	177.8	132.5	314.2	194.5	139	40.3	128.5	185.8	154.8	22.8	156	146.7	78.9

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Neurocrine Biosciences Inc competitor comparison and performance snapshot within industry

Neurocrine Biosciences Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Neurocrine Biosciences Inc Dec-2025 Annual Revenue is $2,860 Million which is growth of 21.4% YoY.
POSITIVE
Annual Net Profit Neurocrine Biosciences Inc Dec-2025 Annual Net Profit is $479 Million which is growth of 40.2% YoY.

Neurocrine Biosciences, Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	24.3%	22.3%		2,860.5	2,355.3	1,887.1	1,488.7	1,133.5	1,045.9	788.1	451.2	161.6	15	19.8
TotalOperatingRevenues_A Operating Rev. Ann.	24.3%	22.3%	3,373.9	2,860.5	2,355.3	1,887.1	1,488.7	1,133.5	1,045.9	788.1	451.2	161.6	15	19.8
CostOfRevenue_A Cost Of Rev. Ann.	31%	38.8%	68.6	52.1	34	39.7	23.2	14.3	10.1	7.4	4.9	1.3	-	-
GrossProfit_A Gross Profit Ann.	24.2%	22.1%	3,305.3	2,808.4	2,321.3	1,847.4	1,465.5	1,119.2	1,035.8	780.7	446.4	160.4	-	-
OEXPNS_A Operating Exp. Ann.	21.3%	25.1%	2,499.1	2,171.9	1,738.3	1,452.6	1,216.5	911.4	708.3	554.1	409.5	291.7	162.4	114
OP_A Operating Profit Ann.	36.7%	14.2%	806.2	636.5	583	394.8	249	207.8	327.5	226.6	36.9	-131.4	-147.4	-94.2
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-	-		90.3	-35.6	-4.6	-7.1	-25.8	-32.8	-32	-30.5	-19.5	2.8	1.9
Others_A Other Interest Earned Ann.	-	-		90.3	91	-	-	-	-	-	-	-	2.8	1.9
IntExpNonOperating_A Interest Exp. Non Operating Ann.	-	-		-	126.6	4.6	7.1	25.8	32.8	32	30.5	19.5	-	-
OtherExpenses_A Other Exp. Ann.	-	-		-21.4	-61.4	-58.1	-28	-80.6	-188	-148.1	15.5	8.3	3.4	3.3
PBT_A PBT Ann.	48.8%	45.9%	940.2	705.4	486	332.1	213.9	101.4	106.7	46.5	21.8	-142.5	-141.1	-88.9
TAX_A Tax Ann.	56.3%	-	234.7	226.8	144.7	82.4	59.4	11.8	-300.6	9.5	0.7	-	-	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	45.8%	3.3%	705.5	478.6	341.3	249.7	154.5	89.6	407.3	37	21.1	-142.5	-141.1	-88.9
NP_A Net Profit Ann.	45.8%	3.3%	705.5	478.6	341.3	249.7	154.5	89.6	407.3	37	21.1	-142.5	-141.1	-88.9
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	45.8%	3.3%	705.5	478.6	341.3	249.7	154.5	89.6	407.3	37	21.1	-142.5	-141.1	-88.9
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	45.8%	3.3%	705.5	478.6	341.3	249.7	154.5	89.6	407.3	37	21.1	-142.5	-141.1	-88.9
EPS_A EPS Ann.	44.2%	1.8%		4.8	3.4	2.6	1.6	1	4.4	0.4	0.2	-1.6	-1.6	-1.1
DilutedEPS_A Diluted EPS Ann.	43.2%	2.3%		4.7	3.3	2.5	1.6	0.9	4.2	0.4	0.2	-1.6	-1.6	-1.1
SHARE_Q Number Of Shares End	1.3%	1.4%		100.1	99.8	98.3	96.4	94.9	93.4	92.2	90.8	88.7	86.9	86.2
TotalExpenses_A Total Exp. Ann.	21.5%	25.4%		2,224	1,772.3	1,492.3	1,239.7	925.7	718.4	561.5	414.3	293	162.4	114
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	45.8%	3.3%	705.5	478.6	341.3	249.7	154.5	89.6	407.3	37	21.1	-142.5	-141.1	-88.9
NormalizedIncome_A Normalized Income Ann.	24%	10.2%	913.9	654.5	656.3	390	343.2	185.8	402.3	283.8	76.5	-102.1	-116.1	-63.9
InterestIncome_A Interest Income Ann.	-	-		90.3	91	-	-	-	-	-	-	-	2.8	1.9
INT_A Interest Ann.	-	-		-	126.6	4.6	7.1	25.8	32.8	32	30.5	19.5	-	-
EBITDA_A EBITDA Ann.	39.7%	34.2%	990.4	645.2	548.7	358	236.6	138.1	148.1	86	56.4	-120.6	-142.5	-89.9
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	31%	38.8%	60.2	52.1	34	39.7	23.2	14.3	10.1	7.4	4.9	1.3	-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	24.5%	28.5%	47.3	30.1	27.1	21.3	15.6	10.9	8.6	7.5	4	2.4	1.5	1
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	45.8%	3.3%	705.5	478.6	341.3	249.7	154.5	89.6	407.3	37	21.1	-142.5	-141.1	-88.9
NormalizedEBITDA_A Normalized EBITDA Ann.	37.5%	15.4%	819	688	701.1	416.1	264.6	218.7	336.1	234	40.9	-129	-149.4	-96.5

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

21.4%

2Y CAGR

23.1%

3Y CAGR

24.3%

5Y CAGR

22.3%

7Y CAGR

30.2%

10Y CAGR

64.4%

Total Revenue Annual growth is lower than historical averages.

Net Profit Ann.

1Y CHG

40.2%

2Y CAGR

38.4%

3Y CAGR

45.8%

5Y CAGR

3.3%

7Y CAGR

56.2%

Net Profit Annual growth is stable compared to historical averages.

Operating Exp. Ann.

1Y CHG

24.9%

2Y CAGR

22.3%

3Y CAGR

21.3%

5Y CAGR

25.1%

7Y CAGR

26.9%

10Y CAGR

34.3%

Operating Expenses Annual Cr growth is stable compared to historical averages.

Neurocrine Biosciences Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Neurocrine Biosciences Inc Dec-2025 Total Shareholders Fund is $3,253 Million which is growth of 25.6% YoY.
POSITIVE
Total Assets Neurocrine Biosciences Inc Dec-2025 Total Assets is $4,632 Million which is growth of 24.5% YoY.

Neurocrine Biosciences, Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	25%	21.7%	4,631.5	3,718.7	3,251.4	2,368.7	2,072.5	1,734.7	1,306	993.2	817.6	365.1	474.8
CA_A Total Current Assets Ann.	20.2%	19.9%	2,522.7	1,724.7	1,607	1,453.5	972.8	1,016.2	831	737.8	554.9	310.4	384.1
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	14.4%	13.1%	1,480.4	1,076.1	1,031.6	989.3	711.3	801	670.5	650.9	515.9	307.4	379.2
Receivables_A Change In Account Receivables Ann.	25.2%	34.3%	686.8	479.1	439.3	350	185.5	157.1	126.6	56.2	31.1	-	-
Inventories_A Inventories Ann.	25.3%	19.8%	69	57.4	38.3	35.1	30.5	28	17.3	10.9	-	-	-
OtherCurrentAssets_A Other Current Assets Ann.	13.5%	30.9%	115.8	112.1	97.8	79.1	45.5	30.1	16.7	19.8	7.9	3.1	4.9
TotalNonCurrentAssets_A Total Non Current Assets Ann.	32.1%	24%	2,108.8	1,994	1,644.4	915.2	1,099.7	718.5	475	255.4	262.7	54.6	90.7
NetPPE_A Net PPE Ann.	55.3%	33.7%	545.2	592	347.3	145.6	155.8	127.4	116.3	33.9	10.8	6.3	3.4
InvestmentsAndAdvances_A Investments & Advances Ann.	43.4%	34.9%	1,183.8	864.3	849.4	401.5	624.4	265.3	355.5	216	247.4	43.5	82.5
OtherNonCurrentAssets_A Other Non Current Assets Ann.	33.5%	56.2%	59.5	15.5	49.6	25	4.4	6.4	3.2	5.5	4.5	4.9	4.8
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	27.8%	17.8%	1,378.4	1,129	1,019.4	660.9	698.5	608.5	669.1	512.4	445.5	50.2	50.3
CL_A Total Current Liabilities Ann.	11.4%	31.9%	743.4	507.7	654.8	537.7	245.8	186.5	565.3	88.2	54.4	30.4	25.7
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	30.8%	27.2%	319.5	210	223.3	142.9	112.5	95.9	71.7	59	28.6	16.6	14.2
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	-	-	-	-	170.1	169.4	-	-	408.8	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	-	-	-	-	-	-	-	0.7	4	3.7
OtherCurrentLiabilities_A Other Current Liabilities Ann.	49.5%	31.2%	69.1	46	35.9	20.7	20	17.8	15.2	1.9	0.2	0.2	0.4
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	72.7%	8.5%	635	621.3	364.6	123.2	452.7	422	103.8	424.2	391	19.8	24.6
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	64.4%	0.1%	415.3	455.1	258.3	93.5	440.4	412.3	86.8	388.5	369.6	-	-
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	214.5	160.7	96	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	24%	23.6%	3,253.1	2,589.7	2,232	1,707.8	1,374	1,126.2	636.9	480.8	372.1	314.9	424.5
EQCAP_A Equity Share Capital Ann.	24%	23.6%	3,253.1	2,589.7	2,232	1,707.8	1,374	1,126.2	636.9	480.8	372.1	314.9	424.5
CapitalStock_A Capital Stock Ann.	0%	0%	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
RetainedEarnings_A Retained Earnings Ann.	-	-	447.7	29.2	-157.1	-406.8	-635.8	-725.4	-1,132.7	-1,177.8	-1,198.9	-1,056.3	-915.2
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	48.7%	13.1	5.8	7	-7.9	-1.7	1.8	1.4	-1.9	-1.9	-0.3	-1
TotalCapitalization_A Total Capitalization Ann.	24%	17.6%	3,253.1	2,589.7	2,232	1,707.8	1,709.1	1,444.1	636.9	869.3	741.8	314.9	424.5
TangibleAssets_A Tangible Assets Ann.	24.9%	23.6%	3,253.1	2,553.2	2,196.5	1,670.6	1,374	1,126.2	636.9	480.8	372.1	314.9	424.5
WC_A Working Capital Ann.	24.8%	16.5%	1,779.3	1,217	952.2	915.8	727	829.7	265.8	649.5	500.5	280	358.4
InvestedCapital_A Invested Capital Ann.	20.1%	17.6%	3,253.1	2,589.7	2,402.1	1,877.2	1,709.1	1,444.1	1,045.7	869.3	741.8	314.9	424.5
TangibleBookValue_A Tangible Book Value Ann.	24.9%	23.6%	3,253.1	2,553.2	2,196.5	1,670.6	1,374	1,126.2	636.9	480.8	372.1	314.9	424.5
Borrowings_A Borrowings Ann.	16.5%	0.1%	415.3	455.1	428.4	262.9	440.4	412.3	495.6	388.5	369.6	-	-
NetDebt_A Net Debt Ann.	-	-	-	-	-	-	-	130.8	296.5	246.8	114.9	-	-
ShareIssued_A Share Issued Ann.	1.2%	1.4%	100.1	99.4	98.7	96.5	94.9	93.5	92.3	90.8	88.8	86.9	86.3
SHARE_Q Number Of Shares End	1.3%	1.4%	100.1	99.8	98.3	96.4	94.9	93.4	92.2	90.8	88.7	86.9	86.2

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

24.5%

2Y CAGR

19.4%

3Y CAGR

25%

5Y CAGR

21.7%

7Y CAGR

24.6%

10Y CAGR

25.6%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

46.4%

2Y CAGR

6.6%

3Y CAGR

11.4%

5Y CAGR

31.9%

7Y CAGR

35.6%

10Y CAGR

40%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

25.6%

2Y CAGR

20.7%

3Y CAGR

24%

5Y CAGR

23.6%

7Y CAGR

31.4%

10Y CAGR

22.6%

Total ShareHolders Funds Annual growth is stable compared to historical averages.

Neurocrine Biosciences Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Neurocrine Biosciences Inc Book Value Per Share is $32 which is growth of 24.2% YoY.
NEUTRAL
ROE Neurocrine Biosciences Inc ROE is 0% which is growth of 0% YoY.

Neurocrine Biosciences, Inc., Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	9.79%	8.89%	6.96%	4.71%	26.79%	3.22%	2.33%	-24.10%	-33.60%	-24.78%
ROE_A ROE Ann. %	-	-	-	14.16%	12.68%	10.03%	7.17%	46.20%	6.62%	4.95%	-41.50%	-38.17%	-28.09%
ROIC_Q ROIC %	-	-	-	3.4	6	4.8	-0.1	29.2	3.2	2.8	1.6	-13.4	-6.7
OPMPCT_A OPM Ann. %	10%	-6.6%	22.25%	24.75%	20.92%	16.73%	18.33%	31.31%	28.75%	8.18%	-81.27%	-982.48%	-476.51%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	0.7	1.1	0.7	0.5	0.5	0.5	0.5	-	-	-
ASETTO_A Asset Turnover Ann. %	-	-	-	0.7	0.7	0.7	0.6	0.7	0.7	0.5	0.3	0	0.1
WCTO_A Working Capital Turnover Ann.	0%	4.2%	1.6	1.9	2	1.6	1.6	1.3	3	0.7	0.3	0.1	0.1
QuickRatio_A Quick Ratio Ann.	-	-	-	3.1	2.3	2.5	3.7	5.1	1.4	8	10.1	10.1	14.8
CRATIO_A Current Ratio Ann.	-	-	-	3.4	2.5	2.7	4	5.5	1.5	8.4	10.2	10.2	14.9
IC_A Interest Coverage Ratio Ann.	-	-	-	4.8	73.2	31.1	4.9	4.3	2.5	1.7	-6.3	-	-
LTDE_A LT Debt To Equity Ann.	-	-	-	0.2	0.1	0.1	0.3	0.4	0.1	0.8	1	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Neurocrine Biosciences Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity Neurocrine Biosciences Inc Dec-2025 Cash From Operating Activity is $783 Million which is growth of 31.5% YoY.
POSITIVE
Net Cash Flow Neurocrine Biosciences Inc Dec-2025 Net Cash Flow is $480 Million which is growth of 2751.9% YoY.

Neurocrine Biosciences, Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	32.1%	27.9%	782.7	595.4	389.9	339.4	256.5	228.5	152.1	101.4	-94.3	-106.2	-38
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	45.8%	3.3%	478.6	341.3	249.7	154.5	89.6	407.3	37	21.1	-142.5	-141.1	-88.9
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	24.5%	28.5%	30.1	27.1	21.3	15.6	10.9	8.6	7.5	4	2.4	1.5	1
DepreciationAndAmortization_A Depreciation And Amortization Ann.	24.5%	28.5%	30.1	27.1	21.3	15.6	10.9	8.6	7.5	4	2.4	1.5	1
DeferredTax_A Deferred Tax Ann.	105.4%	-	165.4	-123.1	-56.7	19.1	4.3	-310.7	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	105.4%	-	165.4	-123.1	-56.7	19.1	4.3	-310.7	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	8%	16.9%	217.9	195.5	194.3	173.1	134.2	100	75.3	58.1	42.5	28.5	28.4
OtherNonCashItems_A Other Non Cash Items Ann.	40.8%	-10%	14.8	162.9	-0.2	5.3	21.7	25.1	21.1	19.2	12.4	-0.9	10.1
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-128.8	-19.2	28.2	-67.4	16.7	-37.9	0.2	-1.8	-8.8	5.8	8.7
ChangeInReceivables_A Change In Receivables Ann.	-	-	-210.5	-39.8	-89.3	-162.2	-28.4	-30.5	-69.2	-25.1	-31.1	1.8	-0.5
ChangeInInventory_A Change In Inventory Ann.	-	-	-15.3	-19.1	5.4	-2.6	-2.5	-10.7	-6.4	-3.5	-1	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	11.8%	42.9%	160.2	29	64.3	114.6	56.8	26.9	54	24.2	27.3	4.4	9.8
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-6	-3.8	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-0.3	-0.4	-0.7
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-63.2	10.7	47.8	-17.2	-9.2	-23.6	21.9	8.7	-	-	-
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-264.4	-126.8	-467.1	-177.1	-130.2	4.1	-211.1	-242.9	-250.9	112.9	-195.8
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-	-	-	-	-23.4	-10.9	-14.7	-24.8	-6.9	-4.1	-1.9
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-	-	-	-	-23.4	-10.9	-14.8	-24.8	-6.9	-4.1	-1.9
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-			-42.7	-	-	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-			-42.7	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-1,319.8	-1,056.1	-1,411.2	-628.9	-804.7	-735.5	-797.2	-546	-583.4	-298.8	-449.1
SaleOfInvestment_A Sale Of Investment Ann.	28.7%	7.7%	1,089.4	967.5	972.4	511	697.9	750.5	669.7	327.8	339.1	415.8	255.1
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	-68.9	-	0.4	-0.1	0
CFA_A Cash from Financing Act. Ann. ⌄	-	-	-38.3	-486.7	65.3	-234.3	27.4	-157.8	27.3	29.5	516.7	2.4	277
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-		-308.8		-279	-0.1	-186.9			502.8	-	-
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-		-		-279	-0.1	-186.9			502.8	-	-
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-308.8		-279	-0.1	-186.9	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-	-167.7	-300	-	-	-	-	27.3	29.5	13.9	2.4	277
CommonStockIssuance_A Common Stock Issuance Ann.	-	-	-	-	-	-	-	-	27.3	29.5	13.9	2.4	277
CommonStockPayments_A Common Stock Payments Ann.	-	-	-167.7	-300	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	38.6%	30.5%	721	241	259.1	270.7	344	190.3	115.5	147.2	254.7	83.3	74.2
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	45%	480	-18.1	-11.9	-72	153.7	74.8	-31.7	-112	171.4	9.1	43.2
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-11.2%	15.8%	241	259.1	270.7	344	190.3	115.5	147.2	259.2	83.3	74.2	31
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	78.1%	39.7%	81.4	217.5	51.5	14.4	5.1	15.3	0.5	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-42.9%	-32.7%		1.6	3.8	6.6	8.6	11.6	11.6	11.6	6.2	-	-
CapitalExpenditure_A Capex Ann.	-	-	-34	-38.2	-28.3	-16.5	-23.4	-10.9	-14.8	-24.8	-6.9	-4.1	-1.9
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-	-	-	-	-	-	-	27.3	29.5	13.9	2.4	277
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	-	-	-	-	-	-			502.8	-	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-		-308.8		-279	-0.1	-186.9	-	-	-	-	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-167.7	-300	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	32.4%	28%	748.7	557.2	361.6	322.9	233.1	217.6	137.3	76.6	-101.3	-110.3	-39.9

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

31.5%

2Y CAGR

41.7%

3Y CAGR

32.1%

5Y CAGR

27.9%

7Y CAGR

33.9%

Cash from Operating Activity Annual growth is stable compared to historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

27.40% Fall from 52W High

Neurocrine Biosciences Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Neurocrine Biosciences Inc - Forecaster

Forecaster Analyst Estimates for Neurocrine Biosciences Inc share price target, revenues, EPS, net income and more

Neurocrine Biosciences Inc - Earnings Report - Quarterly Results

Neurocrine Biosciences Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Neurocrine Biosciences Inc Jun-2026 Quarterly Revenue is $959 Million which is growth of 39.5% YoY.

Quarterly Net Profit Neurocrine Biosciences Inc Jun-2026 Quarterly Net Profit is $144 Million which is growth of 34.3% YoY.

Neurocrine Biosciences Inc - Competitors/Peers

Neurocrine Biosciences Inc competitor comparison and performance snapshot within industry

Neurocrine Biosciences Inc - Earnings Report - Annual Results

Neurocrine Biosciences Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Neurocrine Biosciences Inc Dec-2025 Annual Revenue is $2,860 Million which is growth of 21.4% YoY.

Annual Net Profit Neurocrine Biosciences Inc Dec-2025 Annual Net Profit is $479 Million which is growth of 40.2% YoY.

Neurocrine Biosciences Inc - Balance Sheet

Neurocrine Biosciences Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Neurocrine Biosciences Inc Dec-2025 Total Shareholders Fund is $3,253 Million which is growth of 25.6% YoY.

Total Assets Neurocrine Biosciences Inc Dec-2025 Total Assets is $4,632 Million which is growth of 24.5% YoY.

Neurocrine Biosciences Inc - Ratios

Neurocrine Biosciences Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Neurocrine Biosciences Inc Book Value Per Share is $32 which is growth of 24.2% YoY.

ROE Neurocrine Biosciences Inc ROE is 0% which is growth of 0% YoY.

Neurocrine Biosciences Inc - Cash Flow

Neurocrine Biosciences Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Neurocrine Biosciences Inc Dec-2025 Cash From Operating Activity is $783 Million which is growth of 31.5% YoY.

Net Cash Flow Neurocrine Biosciences Inc Dec-2025 Net Cash Flow is $480 Million which is growth of 2751.9% YoY.